Cure My Disease

Don't miss your cure!

 Log in / Sign up

Proton beams vs. X-Rays: can a pricier radiation spare hearts and prevent second cancers?

NCT ID NCT07817641

Symptom relief Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are studying whether proton therapy is practical on a national scale and whether it reduces late side effects, such as second cancers and heart damage, compared with standard photon radiation. The trial enrolls adults with Hodgkin or non-Hodgkin lymphoma confined to the chest area who are candidates for curative treatment. Participants receive proton therapy instead of photon therapy, and researchers track acute and late toxicities, including heart attacks and secondary cancers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
proton therapy, a form of radiation that targets tumors while sparing nearby healthy tissue
What this could lead to
If proton therapy lowers late heart damage and second cancers, it could become a preferred radiation option for people with mediastinal lymphoma.
What could go wrong
This is a feasibility and comparison study, not a proven fix. Proton therapy is costly and not widely available, and the trial may not show a clear advantage over photon therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 139 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2046

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients 18 years or older * Histologically proven Hodgkin or non-Hodgkin lymphoma * Disease constrained within the mediastinum +/- neck and/or axilla involvement. * Candidates for curative intended treatment * Signed written informed consent. Exclusion Criteria: * Prior radiotherapy to the thorax * Other current malignancy * Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B cell lymphoma (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma Hodgkins lymphoma lymphoma mediastinal malignant lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B cell lymphoma (DLBCL) Hodgkin disease lymphoma Mediastinal lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dept. of oncology

    RECRUITING

    Copenhagen, Select A State, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.